The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is taking two TB drug combinations into Phase II clinical trials to see if one or both of the regimens can effectively treat the disease with a shorter duration of therapy, reducing the burden on both patients and health care systems in resource-constrained countries where TB is most prevalent.
Pharma, Non-Profits Ally To Advance TB Drug Combinations
Goal Is Shorter Duration Treatment Regimens
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is pulling together philanthropic, non-profit and private sector participants to collaboratively run Phase II trials for five drugs from Janssen, Otsuka, the TB Alliance and the Bill & Melinda Gates Medical Research Institute.
More from Anti-infective
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.